Matrix metalloproteinase 14 modulates diabetes and Alzheimer's disease cross-talk: a meta-analysis.
Jack ChengHsin-Ping LiuCheng-Chun LeeMei-Ying ChenWei-Yong LinFuu-Jen TsaiPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2017)
Diabetes mellitus is associated with dementia, but whether diabetes is associated with Alzheimer's disease remains controversial. Alzheimer's disease is characterized by amyloid beta aggregation. We hypothesized that genes, involved in amyloid beta degradation, may be altered due to diabetes and thus participate in progression of Alzheimer's disease. Expression profiling of amyloid beta-degrading enzymes in streptozotocin-induced diabetic mice and their correlation with expression of amyloid precursor protein in hippocampus of Alzheimer's disease patients were accessed. We found that matrix metalloproteinase 14 decreased in brain but not in other tissues of streptozotocin-induced diabetic mice, and was negatively correlated with expression of amyloid precursor protein in hippocampus of Alzheimer's disease patients. These findings suggested matrix metalloproteinase 14 may link insulin-deficient diabetes to Alzheimer's disease.
Keyphrases
- type diabetes
- cognitive decline
- cardiovascular disease
- glycemic control
- diabetic rats
- gene expression
- poor prognosis
- ejection fraction
- prognostic factors
- mild cognitive impairment
- binding protein
- multiple sclerosis
- long non coding rna
- skeletal muscle
- transcription factor
- brain injury
- cerebral ischemia
- blood brain barrier
- diabetic nephropathy